| Nov 13 |
Lucid Diagnostics Inc. (LUCD) Q3 2024 Earnings Call Transcript
|
| Nov 13 |
Lucid Diagnostics Inc. 2024 Q3 - Results - Earnings Call Presentation
|
| Nov 13 |
Lucid Diagnostics reports Q3 results
|
| Nov 13 |
Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial Results
|
| Nov 13 |
Earnings Scheduled For November 13, 2024
|
| Nov 7 |
Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication
|
| Nov 5 |
Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers
|
| Oct 31 |
PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024
|
| Oct 30 |
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024
|
| Oct 15 |
Lucid Diagnostics gets notice of allowance for patent underlying its esoguard esophageal DNA test
|
